Diabetes classification: grey zones, sound and smoke: Action LADA 1

被引:85
作者
Leslie, R. D. G. [1 ]
Kolb, H. [2 ]
Schloot, N. C. [2 ]
Buzzetti, R. [4 ]
Mauricio, D. [5 ]
De Leiva, A. [5 ]
Yderstraede, K. [6 ]
Sarti, C. [7 ]
Thivolet, C. [8 ]
Hadden, D.
Hunter, S. [9 ]
Schernthaner, G. [10 ]
Scherbaum, W. [2 ,3 ]
Williams, R. [11 ]
Pozzilli, P. [12 ]
机构
[1] Univ London, Inst Cell & Mol Sci, London E1 2AT, England
[2] German Diabet Ctr, Dusseldorf, Germany
[3] Univ Hosp, Dusseldorf, Germany
[4] Univ Roma La Sapienza, Rome, Italy
[5] Hosp Santa Creu & Sant Pau, Barcelona, Spain
[6] Odense Univ Hosp, DK-5000 Odense, Denmark
[7] Natl Publ Hlth Inst, Helsinki, Finland
[8] Hosp Edouard Herriot, Lyon, France
[9] Royal Victoria Hosp, Belfast BT12 6BA, Antrim, North Ireland
[10] Rudolfstiftung Hosp, Vienna, Austria
[11] Swansea Univ, Swansea, W Glam, Wales
[12] Univ Campus Biomed, Rome, Italy
关键词
type; 1; diabetes; 2; LADA; insulin secretion; insulin resistance; age at onset of diabetes; GADA; ketosis-prone diabetes;
D O I
10.1002/dmrr.877
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diseases gain identity from clinical phenotype as well as genetic and environmental aetiology. The definition of type 1 diabetes is clinically exclusive, comprising patients who are considered insulin dependent at diagnosis, whilst the definition of type 2 diabetes is inclusive, only excluding those who are initially insulin dependent. Ketosis-prone diabetes (KPD) and latent autoimmune diabetes in adults (LADA) are each exclusive forms of diabetes which are, at least initially, clinically distinct from type 2 diabetes and type 1 diabetes, and each have a different natural history from these major types of diabetes. KPD can be diagnosed unequivocally as diabetes presenting with the categorical clinical feature, ketoacidosis. in contrast, LADA can be diagnosed by the co-occurrence of three traits, not one of which is categorical or exclusive to the condition: adult-onset non-insulin-requiring diabetes, an islet autoantibody such as glutamic acid decarboxylase autoantibodies (GADA) or cytoplasmic islet cell autoantibodies (ICA), and no need for insulin treatment for several months post-diagnosis. But while some would split diabetes into distinct subtypes, there is a strong case that these subtypes form a continuum of varying severity of immune and metabolic dysfunction modified by genetic and non-genetic factors. This article discusses the nature of disease classification in general, and KPD and LADA in particular, emphasizing the potential value and pitfalls in classifying diabetes and suggesting a need for more research in this area. Copyright (c) 2008 John Wiley & Sons, Ltd.
引用
收藏
页码:511 / 519
页数:9
相关论文
共 66 条
[1]   Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes [J].
Agardh, CD ;
Cilio, CM ;
Lethagen, Å ;
Lynch, K ;
Leslie, RDG ;
Palmér, M ;
Harris, RA ;
Robertson, JA ;
Lernmark, Å .
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2005, 19 (04) :238-246
[2]   MICA marks additional risk factors for Type 1 diabetes on extended HLA haplotypes:: An association and meta-analysis [J].
Alizadeh, Behrooz Z. ;
Eerligh, Peter ;
van der Slik, Arno R. ;
Shastry, Arun ;
Zhernakova, Alexandra ;
Valdigem, Gustavo ;
Bruining, Jan G. ;
Sanjeevi, Carani B. ;
Wijmenga, Cisca ;
Roep, Bart O. ;
Koeleman, Bobby P. C. .
MOLECULAR IMMUNOLOGY, 2007, 44 (11) :2806-2812
[3]   Accuracy and predictive value of classification schemes for ketosis-prone diabetes [J].
Balasubramanyam, Ashok ;
Garza, Gilberto ;
Rodriguez, Lucille ;
Hampe, Christiane S. ;
Gaur, Lakshmi ;
Lernmark, Ake ;
Maldonado, Mario R. .
DIABETES CARE, 2006, 29 (12) :2575-2579
[4]   GAD ANTIBODY NEGATIVE NIDDM IN ADULT BLACK SUBJECTS WITH DIABETIC-KETOACIDOSIS AND INCREASED FREQUENCY OF HUMAN-LEUKOCYTE ANTIGEN DR3 AND DR4 - FLATBUSH DIABETES [J].
BANERJI, MA ;
CHAIKEN, RL ;
HUEY, H ;
TUOMI, T ;
NORIN, AJ ;
MACKAY, IR ;
ROWLEY, MJ ;
ZIMMET, PZ ;
LEBOVITZ, HE .
DIABETES, 1994, 43 (06) :741-745
[5]   Type 1 diabetes is associated with increased cyclooxygenase- and cytokine-mediated inflammation [J].
Basu, S ;
Vessby, B ;
Larsson, A ;
Berne, C ;
Vessby, J .
DIABETES CARE, 2005, 28 (06) :1371-1375
[6]   Insulin resistance in latent autoimmune diabetes of adulthood [J].
Behme, MT ;
Dupré, J ;
Harris, SB ;
Hramiak, IM ;
Mahon, JL .
IMMUNOLOGY OF DIABETES II: PATHOGENESIS FROM MOUSE TO MAN, 2003, 1005 :374-377
[7]   Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk [J].
Bingley, PJ ;
Gale, EAM .
DIABETOLOGIA, 2006, 49 (05) :881-890
[8]   Diabetes antibody standardization program: First assay proficiency evaluation [J].
Bingley, PJ ;
Bonifacio, E ;
Mueller, PW .
DIABETES, 2003, 52 (05) :1128-1136
[9]   Haemophilias A and B [J].
Bolton-Maggs, PHB ;
Pasi, KJ .
LANCET, 2003, 361 (9371) :1801-1809
[10]   IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71) [J].
Bottazzo, GF ;
Bosi, E ;
Cull, CA ;
Bonifacio, E ;
Locatelli, M ;
Zimmet, P ;
Mackay, IR ;
Holman, RR .
DIABETOLOGIA, 2005, 48 (04) :703-708